Skip to content

Study · Not a test of the peptide alone · 2025

8 results

Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial.

Yu J, Yin L, Guo W, Wang Q, Liu J, Zhang L, Ye H, Xia J, Xia Y, Wu J, Wang W, Yang Y and 4 more

Show all authors

Zong D, He X, Wang L, Jiang H

Cancer immunology, immunotherapy : CII4 Feb 2025Cited by 10 (Europe PMC)

PMID39904914 (opens in a new tab)PMCIDPMC11794727 (opens in a new tab)DOI10.1007/s00262-024-03934-9 (opens in a new tab)PepBankPUB-39904914
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In heavily treated metastatic solid tumors, a regimen of HFRT, camrelizumab, GM-CSF and thymosin-α1 gave a median progression-free survival of 3.5 months.

    In plain wordsIn patients with advanced solid tumors, a multi-drug plan that included thymosin alpha‑1 gave a median of 3.5 months without progression.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableMedian progression-free survival
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Measurements

    Median PFS
    3.5 months
    ITT population

    Source sentences

    Summary
    Median progression-free survival was 3.5 months (95% confidence interval 2.73-4.23) in the intention-to-treat population.
    2 context sentences
    Summary · context
    This multicenter Phase II clinical study assessed the efficacy and safety of hypofractionated radiotherapy (HFRT) in combination with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1 in patients with heavily treated metastatic solid tumors.
    Summary · context
    By June 15, 2024, there were 37 study participants.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In heavily treated metastatic solid tumors, the regimen gave an objective response rate of 23.08%.

    In plain wordsIn patients with advanced solid tumors, a multi-drug plan that included thymosin alpha‑1 shrank tumors in 23.08% of patients.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableObjective response rate
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Measurements

    Objective response rate
    23.08%
    regimen

    Source sentences

    Summary
    The objective response rate was 23.08%
    2 context sentences
    Summary · context
    This multicenter Phase II clinical study assessed the efficacy and safety of hypofractionated radiotherapy (HFRT) in combination with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1 in patients with heavily treated metastatic solid tumors.
    Summary · context
    By June 15, 2024, there were 37 study participants.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In heavily treated metastatic solid tumors, the regimen gave a disease control rate of 65.38%.

    In plain wordsIn patients with advanced solid tumors, a multi-drug plan that included thymosin alpha‑1 controlled disease in 65.38% of patients.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableDisease control rate
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Measurements

    Disease control rate
    65.38%
    regimen

    Source sentences

    Summary
    and the disease control rate was 65.38%.
    2 context sentences
    Summary · context
    This multicenter Phase II clinical study assessed the efficacy and safety of hypofractionated radiotherapy (HFRT) in combination with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1 in patients with heavily treated metastatic solid tumors.
    Summary · context
    By June 15, 2024, there were 37 study participants.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    Abscopal effects were observed in 6 patients (23.08%) on the regimen, four of whom achieved a partial response.

    In plain wordsIn patients with advanced solid tumors, tumors outside the radiation field shrank in 6 patients on a multi-drug plan that included thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableAbscopal effects
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Measurements

    Abscopal effect rate
    23.08%
    regimen

    Source sentences

    Summary
    Abscopal effects were observed in 6 patients (23.08%); four of whom achieved a partial response.
    2 context sentences
    Summary · context
    This multicenter Phase II clinical study assessed the efficacy and safety of hypofractionated radiotherapy (HFRT) in combination with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1 in patients with heavily treated metastatic solid tumors.
    Summary · context
    By June 15, 2024, there were 37 study participants.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    Patients with a partial response were significantly more likely to have an abscopal effect.

    In plain wordsIn this trial, patients whose tumors responded were more likely to also show tumor shrinkage outside the radiation field.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableAbscopal effect by partial response
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Patients who achieved a partial response were significantly more likely to have an abscopal effect( P = 0.025).
    2 context sentences
    Summary · context
    This multicenter Phase II clinical study assessed the efficacy and safety of hypofractionated radiotherapy (HFRT) in combination with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1 in patients with heavily treated metastatic solid tumors.
    Summary · context
    By June 15, 2024, there were 37 study participants.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    A lower baseline neutrophil-lymphocyte ratio was linked to significantly lower risks of distant metastasis and death.

    In plain wordsIn this trial, patients with a lower blood cell ratio at the start had lower risk of spread and death.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableNeutrophil-lymphocyte ratio and risk of distant metastasis and death
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The group with a lower baseline neutrophil-lymphocyte ratio had a significantly lower risks of distant metastasis and death( P = 0.024).
    2 context sentences
    Summary · context
    This multicenter Phase II clinical study assessed the efficacy and safety of hypofractionated radiotherapy (HFRT) in combination with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1 in patients with heavily treated metastatic solid tumors.
    Summary · context
    By June 15, 2024, there were 37 study participants.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    Seventeen adverse reactions were reported with the regimen, including six grade 3 or 4 adverse events.

    In plain wordsIn patients on a multi-drug plan that included thymosin alpha‑1, seventeen side effects were reported, six of them severe.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableAdverse reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Seventeen adverse reactions were reported, including six grade 3 or 4 adverse events.
    2 context sentences
    Summary · context
    This multicenter Phase II clinical study assessed the efficacy and safety of hypofractionated radiotherapy (HFRT) in combination with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1 in patients with heavily treated metastatic solid tumors.
    Summary · context
    By June 15, 2024, there were 37 study participants.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 08HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    No grade 5 adverse events occurred with the regimen.

    In plain wordsIn patients on a multi-drug plan that included thymosin alpha‑1, no side effects led to death.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeGrade 5 adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    There were no grade 5 adverse events.
    2 context sentences
    Summary · context
    This multicenter Phase II clinical study assessed the efficacy and safety of hypofractionated radiotherapy (HFRT) in combination with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1 in patients with heavily treated metastatic solid tumors.
    Summary · context
    By June 15, 2024, there were 37 study participants.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.